Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2021 - 2026)

Gyre Therapeutics has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at -$0.02 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.01 through Dec 2025, down 80.0% year-over-year, with the annual reading at $0.02 for FY2025, 60.0% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q4 2025 at Gyre Therapeutics, down from $0.03 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.64 in Q2 2022 and troughed at -$1.51 in Q4 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.01 (2025), against an average of -$0.23.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 356.25% in 2022 against a maximum downside of 100.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.64 in 2021, then crashed by 100.0% to -$1.28 in 2022, then fell by 17.97% to -$1.51 in 2023, then soared by 100.66% to $0.01 in 2024, then plummeted by 300.0% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EPS (Weighted Average and Diluted) are -$0.02 (Q4 2025), $0.03 (Q3 2025), and $0.01 (Q3 2024).